DrugBank ID:

DB08814

Description:

Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative. The benefits of this agent are the lack of action over the arachidonic acid pathway, the driven production of nitric oxide and the increase of cyclic nucleotide concentration on endothelial cells. The latest translates into the expansion of peripheral blood vessels.It is very important as a secondary prevention of ischemic stroke by offering a lower risk of bleeding.It was developed by J. Uriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada. [DrugBank]

Targets:

Prostaglandin G/H synthase 1 (Humans); Nuclear factor NF-kappa-B p105 subunit (Humans); Nitric oxide synthase, inducible (Humans); cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (Humans) [DrugBank]

Pharmacodynamics:

Triflusal is an antithrombotic anticoagulant. It irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1. Triflusal affects many other targets such as NF kappa B, which is a gene expression regulatory factor for cycloxygenase-a and cytokines. Numerous studies comparing the efficacy and safety profile (i.e. systemic hemorrhage) between triflusal and acetylsalsylic acid has shown either no significant difference or a better effacy and safety profile for triflusal. Triflusal has been shown to protect cerebral tissue due to its inhibition of lipid peroxidation resulting from anoxia-reoxygenation.1 [DrugBank]

SMILES:

CC(=O)Oc1cc(C(F)(F)F)ccc1C(=O)O

2D structures:  

3D structures: